NCT05285358View on ClinicalTrials.gov

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

October 11, 2028

Study Completion Date

October 11, 2028

Conditions
Distal Bile Duct AdenocarcinomaGallbladder CarcinomaIntrahepatic CholangiocarcinomaMetastatic Malignant Neoplasm in the PeritoneumStage IV Distal Bile Duct Cancer AJCC v8Stage IV Intrahepatic Bile Duct Cancer AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Stage IVB Gallbladder Cancer AJCC v8
Interventions
DRUG

Cisplatin

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Nab-paclitaxel

Given via PIPAC

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER